康臣药业2023 中期报告

Contents目錄 Corporate Information2-4Financial Highlights5Management Discussion and Analysis6-19Consolidated Statement of Profit or Loss20Consolidated Statement of Profit or Loss andOther Comprehensive Income21Consolidated Statement of Financial Position22-23Consolidated Statement of Changes in Equity24-26Condensed Consolidated Cash Flow Statement27-28Notes to the Unaudited Interim Financial Report29-55Review Report56-57Other Information58-76 公司資料Corporate Information DIRECTORS 董事 執行董事 Executive Directors Mr. An Meng(Chairman)Ms. Li Qian(Vice Chairlady, Chief Executive Officer)Professor Zhu QuanMr. Xu Hanxing 非執行董事 Non-Executive Director Ms. Zhang Lihua 獨立非執行董事 Independent Non-Executive Directors Mr. Su YuanfuMr. Feng ZhongshiMs. Chen Yujun AUDIT COMMITTEE 審核委員會 Ms. Chen Yujun(Committee Chairlady)Mr. Feng ZhongshiMr. Su Yuanfu 提名委員會 NOMINATION COMMITTEE Mr. Su Yuanfu(Committee Chairman)Mr. An MengMs. Chen Yujun REMUNERATION COMMITTEE 薪酬委員會 Mr. Feng Zhongshi(Committee Chairman)Ms. Li QianMr. Su Yuanfu ENVIRONMENTAL, SOCIAL AND GOVERNANCECOMMITTEE 環境、社會及管治委員會 Mr. An Meng(Committee Chairman)Mr. Feng ZhongshiMs. Chen Yujun 公司秘書 COMPANY SECRETARY Mr. Yau Chi Ming(CPA) AUTHORISED REPRESENTATIVES FOR THEPURPOSE OF THE LISTING RULES 就上市規則而言的授權代表 Mr. An MengMr. Yau Chi Ming 核數師 AUDITOR 108 KPMGPublic Interest Entity Auditor registered in accordancewith the Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater Road, Central, Hong Kong 法律顧問（香港法律） LEGAL ADVISER (AS TO HONG KONG LAW) 1922 Li & Partners22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong 註冊地址 REGISTERED ADDRESS Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HEADQUARTERS IN THE PRC 中國總部 71 71, Dongpeng AvenueEastern section, Guangzhou Economic and TechnologicalDevelopment District Guangzhou, PRC 香港主要營業地點 PRINCIPAL PLACE OF BUSINESS IN HONG KONG 1922 22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong 公司資料Corporate Information 香港聯絡辦公室 LIAISON OFFICE IN HONG KONG 62803 Room 803Wing On Plaza62 Mody RoadTsimshatsui, Kowloon PRINCIPAL BANKERS 主要往來銀行 Bank of China (Hong Kong) LimitedBNP ParibasChina Construction BankChina Merchants BankDBS BankIndustrial and Commercial Bank of ChinaThe Hongkong and Shanghai Banking Corporation Limited 主證券登記處 PRINCIPAL SHARE REGISTRAR Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 香港證券登記分處 183171712-1716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17th Floor Hopewell Centre183 Queen’s Road EastWanchai, Hong Kong 公司網站 COMPANY WEBSITE www. chinaconsun.com www.chinaconsun.com 股份代號 STOCK CODE 1681 管理層討論及分析Management Discussion and Analysis Thefollowing discussion and analysis should be read inconjunctionwith the unaudited interim financial report ofConsun Pharmaceutical Group Limited (the “Company”) andits subsidiaries (collectively, the “Group”). The interim financialreport of the Group has been prepared in accordance withHKAS 34, Interim Financial Reporting. 本公司本集團34 業務與財務回顧 BUSINESS AND FINANCIAL REVIEW 銷售收入 Sales Revenue Forthe six months ended 30 June 2023,the Group’srevenue was RMB1,119,679,000, representing an increase ofapproximately 12.7% as compared with RMB993,528,000 forthe same period last year. 20236301,119,679,000993,528,00012.7% 13.4%8.8%23.7%21.3%272.6%31.9%50.3% Categorizedby product lines,sales of kidney medicinesrecorded an increase of approximately 13.4% as comparedwiththe same period last year,among which,UremicClearanceGranules remained as the Group’s key productandmaintained its leading position in the market;sales ofmedicalcontrast medium recorded a decrease of 8.8%ascompared with the same period last year,and stillmaintaineda leading position in the domestic medicalcontrastmedium market for magnetic resonance imaging;salesof orthopedics medicines recorded a decrease ofapproximately 23.7% as compared with the same period lastyear; sales of dermatologic medicines recorded a decrease ofapproximately 21.3% as compared with the same period lastyear; sales of hepatobiliary medicines recorded an increase ofapproximately 272.6% as compared with the same period lastyear; sales of gynaecology and paediatric medicines recordedan increase of 31.9% as compared with the same period lastyear; and sales of other medicines recorded an increase ofapproximately 50.3% as compared with the same period lastyear. The increase in overall sales revenue was mainly due tothe Group’s constant commitment to expanding the productmarkets and developing the sales network across China. 管理層ী論及分析Management Discussion and Analysis 毛利與毛利率 Gross Profit and Gross Profit Margin 2 0 2 38 3 6 , 4 1 6 , 0 0